Prima Biomed Ltd (PBMD) 0.85 $PBMD European Patent

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Prima Biomed Ltd (PBMD) 0.85 $PBMD

European Patent Grants for IMP731 Antibody
Marketwire Canada - Wed Aug 24, 7:37PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Aug 24, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the European Patent Office.
PBMD: 0.85 (unch)

Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
Marketwire Canada - Wed Aug 10, 2:56AM CDT
SYDNEY, AUSTRALIA--(Marketwired - Aug 10, 2016) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company", has received notification from the Listing Qualifications Department of The NASDAQ Stock Market (the "Staff" indicating that, for the period from June 24, 2016 through August 5, 2016, the closing bid price of the Company's American Depositary Shares, or ADS, had not been maintained at the minimum required closing bid price of at least US$1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule".
PBMD: 0.85 (unch)

Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.85 (unch), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), CELG: 105.49 (-0.88)

Prima BioMed to Maintain NASDAQ Listing
Marketwired - Mon Jun 06, 8:25PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 20 May 2016 to 3 June 2016. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule" and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market.
PBMD: 0.85 (unch)

Prima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) Program
Marketwired - Thu May 12, 3:26AM CDT
SYDNEY, AUSTRALIA and SEATTLE, WA--(Marketwired - May 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.85 (unch)

Prima BioMed Limited (NASDAQ: PBMD) Analyst Coverage Initiated
ACCESSWIRE - Tue May 03, 7:05AM CDT
SYDNEY, AUSTRALIA / ACCESSWIRE / May 3, 2016 / Prima BioMed Limited (NASDAQ: PBMD) an Australia-based biotechnology company engaged in research, development and commercialization of licensed medical biotechnology, recently announced the granting of patent number 5908210 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the Japanese Patent Office. This patent relates to Prima's IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima's AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3rd of October 2028.
PBMD: 0.85 (unch)

Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 0.85 (unch), EBIO: 4.84 (-0.05), OCLS: 4.14 (+0.01)

Prima BioMed wins US patent for IMP731 Antibody
M2 - Thu Jan 28, 3:34AM CST
Biotechnology company Prima BioMed (ASXRR) (NASDAQBMD) disclosed on Wednesday the receipt of the patent entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" from the US Patent and Trademark Office.
PBMD: 0.85 (unch)

US Patent Grants for IMP731 Antibody
Marketwired - Wed Jan 27, 5:00PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" announces the granting of patent number US 9,244,059 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the United States Patent and Trademark Office.
PBMD: 0.85 (unch)

Prima BioMed to start Phase I melanoma study of IMP321 across Australia
M2 - Wed Jan 27, 3:16AM CST
Immuno-oncology company Prima BioMed (ASXRR) (NASDAQBMD) announced on Tuesday that TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, will now commence in the Gallipoli Medical Research Foundation at the Greenslopes Private Hospital in Queensland, Austrlaia.
PBMD: 0.85 (unch)

Prima BioMed Initiates Phase I Melanoma Study in Australia
Marketwired - Tue Jan 26, 4:51PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, to be conducted in Australia.
PBMD: 0.85 (unch)

Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
Marketwired - Tue Dec 22, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.85 (unch)

4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Fri Dec 11, 8:51AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
EYES: 3.44 (+0.08), PBMD: 0.85 (unch), CGEN: 7.41 (+0.36), ONTY: 1.21 (+0.02)

Prima BioMed Progresses Japanese Collaboration
Marketwired - Fri Dec 11, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. In this collaboration, first announced in May 2015, Prima's IMP321 Antigen Presenting Cell activator (APC) is being combined with a therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University.
PBMD: 0.85 (unch)

Prima BioMed Unveils Phase I Combination Study of IMP321 + Checkpoint Inhibitor
Marketwired - Wed Nov 18, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.85 (unch)

Prima BioMed announces AUD2.0m from equity placement with an Australian Institution
M2 - Mon Nov 02, 4:19AM CST
Immuno-oncology company Prima BioMed (ASXRR) (NASDAQBMD) said on Friday that it has raised AUD2.0m in an equity placement with an Australian Institution.
PBMD: 0.85 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 101

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 103

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 76

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 62

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading

Top 5 Most Recently Viewed Articles

Redsun Properties Faces $350 Million Bond Payment Crisis Ahead

Updated Category News Views 189

Redsun Properties Announces Inability to Pay Bond Chinese property developer Redsun Properties has communicated its inability to meet a $350 million bond payment, which is due shortly. This situation has raised considerable concern within the financial markets as it highlights the ongoing issues facing property developers in China. Details of the Bond Issue This bond,...

Continue Reading
Etruscus Resources Unveils Promising Findings at Zappa Target

Updated Category News Views 135

Etruscus Resources Makes Progress at Key Exploration Sites Etruscus Resources Corp. is thrilled to report on the encouraging findings from its exploration program at the Rock & Roll Property. This property is situated in the Golden Triangle region, known for its wealth of mineral resources. The exploration program, which included comprehensive rock sampling and geological...

Continue Reading
MetLife's Strategic Focus: Navigating Q3 2024 Earnings

Updated Category News Views 1091

MetLife Announces Q3 2024 Results and New Frontier Strategy In the third quarter of 2024, MetLife, Inc. (MET) reported adjusted earnings of $1.4 billion, translating to $1.93 per share. This reflects a decline from previous year figures, yet a 12% year-to-date increase in adjusted earnings per share (EPS) excluding notable items. The insurance powerhouse has seen positive...

Continue Reading
VEON Invests in Ukraine: Commitment to Digital Growth

Updated Category News Views 125

VEON's Commitment to Investing in Ukraine VEON Ltd. (NASDAQ: VEON), a leading global digital operator, has recently made significant news with its promise to enhance Ukraine’s telecommunications infrastructure. In collaboration with its fully-owned subsidiary, Kyivstar, VEON participated in the 2024 Yalta European Strategy (YES) Annual Meeting. At this event, the focus...

Continue Reading
Expanding Diabetes Care: From Monitoring to Change

Updated Category News Views 44

Breaking Ground at the AGP & DTx Summit Diabetes management ain't what it used to be, and the 4th AGP & DTx Summit in Shenzhen gave us an eyeful of change. Under the banner "Beyond Glucose," experts from all corners came together to talk shop about Continuous Glucose Monitoring (CGM) and how it might shake up diabetes care. CGM: More Than a Gadget See, CGM's not just a...

Continue Reading